查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1832360

牛呼吸道疾病治療市場（依產品類型、給藥途徑、動物類型和通路）－2025-2032 年全球預測

Bovine Respiratory Disease Treatment Market by Product Type, Route Of Administration, Animal Type, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，牛呼吸道疾病治療市場將成長至 38.4 億美元，複合年成長率為 7.80%。

主要市場統計數據
基準年2024年 21億美元
預計2025年 22.7億美元
預測年份：2032年 38.4億美元
複合年成長率（%） 7.80%

牛呼吸道疾病治療的策略方法使治療選擇與臨床現實、監管趨勢和業務重點保持一致。

牛呼吸道疾病仍是全球畜牧生產系統中最持久且經濟影響最大的健康挑戰之一。本出版物將讀者置於臨床、藥物開發和供應鏈演變的交匯點，重點關注臨床促進因素、監管壓力和生產經濟因素如何影響治療策略。疾病本身包含病毒和細菌病因，通常需要綜合治療和預防，而抗生素和疫苗的相互作用是有效控制計畫的關鍵。

臨床醫生和牛管理者越來越依賴實證通訊協定，以平衡動物福利、抗菌藥物管理和營運效率。在此背景下，治療方法選擇受到病原體流行情況、動物類別、給藥途徑的適宜性以及分銷管道的可及性的影響。此外，監管變化和對減少抗菌藥物使用的日益重視使情況更加複雜，從而增強了有針對性的疫苗接種計劃和替代給藥方法的作用。

因此，本出版物將圍繞四大支柱組裝後續分析：治療方式和劑型、給藥途徑和農場物流、動物人口統計考量以及分銷生態系統。透過圍繞這些支柱展開討論，讀者將獲得實用指導，以支援產品開發、臨床實施和商業規劃方面的策略決策。

科學創新、不斷發展的管理方法和分佈重新配置如何重塑治療策略和臨床實踐範式

由於科學創新、監管調整和生產方法的改變，牛呼吸道疾病的治療格局正在發生重大變化。疫苗技術和製劑科學的進步使得預防主要病毒和細菌的多種選擇成為可能，包括去活化疫苗和減毒活病毒疫苗。同時，抗生素種類和給藥策略的改進正在推進抗菌藥物管理的目標，同時又不犧牲臨床患病動物的治療效果。

同樣重要的是給藥方法的改變。雖然腸外給藥仍然是快速全身治療的主要方式，但經鼻吸入型疫苗和透過飼料或水口服給藥由於易於批量給藥和減少操作壓力，正獲得實際支持。這些變化與牲畜人口統計相關。成年牛和幼牛（例如肉牛和酪農）的治療方案差異很大，成年牛需要不同的管理考慮，而幼牛的免疫成熟度和管理系統會影響預防和治療的時間。

分銷系統也在同步發展。傳統獸醫管道仍在提供臨床監督和處方箋治療，而商業性和農場飼料廠以及線上動物保健平台正在重塑獲取和採購行為。這些趨勢共同迫使產品開發商和供應商重塑市場策略，並促進製藥、飼料和獸醫服務供應商之間建立新的聯盟。

近期關稅政策更新對供應鏈、採購實踐以及獲得牛健康必需治療的連續性的實際影響

美國2025年關稅議程的進展正在影響整個動物用藥品生態系統的供應鏈決策、採購策略和成本結構。進口關稅和海關通訊協定的變化正在影響成品藥品、疫苗成分和活性成分的分銷，迫使製造商和經銷商重新評估籌資策略和庫存配置，以保持供應的連續性。擁有複雜全球供應鏈的公司被迫評估近岸外包、雙重採購和策略性儲備，以作為應對關稅衝擊的緩解策略。

這些轉變將對從飼料廠營運商到獸醫診所等相關人員產生下游影響。採購藥物預混料的飼料預混合料和採購治療藥物的農場工廠現在面臨到岸成本的變化，這可能會影響透過飼料或水給藥的口服藥物的定價和供應。同樣，線上動物用藥品平台和進口利基配方的一般電子零售商可能會調整其產品目錄，以應對利潤壓力和合規複雜性。對於動物生產者而言，實際影響是需要重新關注預防措施，例如進行疫苗宣傳活動以減少對進口治療藥物的依賴，並密切注意採購時間表和供應商的可靠性。

監管協調和貿易便利化措施仍是關鍵變數。在關稅變化造成摩擦的情況下，諸如集中採購、供應商多元化和本地配方開發等行業協作應對措施正在成為切實可行的應對措施。這些應對措施優先考慮持續獲得基本治療和疫苗，同時確保遵守臨床方案和管理職責。

將治療類別、給藥途徑、動物統計數據和分銷管道與臨床和商業策略聯繫起來的詳細細分觀點

細分洞察揭示了不同產品類別、給藥途徑、動物類型和分銷管道的差異化商業機會和臨床考慮。依產品類型分類，抗生素涵蓋藥理學上不同的類別，例如BETA-內醯胺類、Fluoroquinolones、大環內酯類和四環黴素，其中大環內酯類的代表藥物包括替米考星、泰拉黴素和泰樂菌素。疫苗具有預防作用，分為牛呼吸道融合細胞病毒、巴氏桿菌和副流感病毒3型等病原體的去活化疫苗，以及針對牛呼吸道合胞病毒、曼氏桿菌和PI3型等病原體的減毒活病毒疫苗。

給藥途徑是關鍵的細分視角。當需要全身濃度和快速起效時，肌肉注射、靜脈注射或皮下注射仍然是標準。另一方面，透過飼料或飲水給藥的口服製劑可以實現大劑量給藥策略並減少操作，但需要謹慎給藥並考慮偏好。牛（包括肉牛和乳牛）與牛和小母牛相比，有不同的生產目標和管理限制，免疫能力和管理系統的脆弱性會影響給藥時機和方案選擇。肉牛和牛酪農系統中的牛可能需要更早針對每牛採取預防性干預措施和治療方法。

分銷通路細分強調服務和物流方面。飼料廠（商業和農場）在供應藥物飼料和支持口服給藥策略方面發揮重要作用。線上藥局充當動物保健平台和通用電子零售管道，在法律規範允許的情況下擴大產品獲取管道。從獨立診所到大型多設施集團的獸醫院繼續提供臨床監督、診斷和處方箋治療。了解這些相互交叉的細分市場，有助於相關人員將產品開發、包裝、低溫運輸設計和商業模式與最終用戶需求和營運實際情況相結合。

當地生產系統、法規環境和分銷基礎設施如何影響差異化治療方式和部署策略

美洲、歐洲、中東和非洲以及亞太地區的區域動態決定了臨床重點、監管預期和分銷策略。在美洲，從大型商業飼養場到家庭經營的酪農，各種生產系統意味著多樣化的治療需求，因此管理計劃和可追溯性至關重要。疫苗宣傳活動和有針對性的抗生素治療方案透過獸醫網路和一體化供應鏈進行協調，飼料廠和獸醫診所在產品分銷中發揮關鍵作用。

在歐洲、中東和非洲，法律規範和管理舉措通常鼓勵保守使用抗生素並更多地採用預防策略。該地區展現出一系列基礎設施能力，從歐洲部分地區高度發達的低溫運輸系統到部分中東和北非市場較為分散的分銷網路，影響了減毒活病毒疫苗和注射劑的實用化。亞太地區的特點是集約化生產系統的快速成長、多樣化的法規環境以及線上動物用藥品平台和商業飼料廠的作用不斷擴大。在許多亞太市場，生產規模和與製造地的接近性創造了獨特的物流優勢和挑戰，尤其是對於透過飼料或水進行治療而言。

在整個全部區域，對相關人員的實際影響包括：使產品形式與物流現實一致，考慮監管和管理框架，並根據當地採購實踐調整商業性方法。因此，跨區域知識轉移和適應性實施策略對於成功開展治療和預防計畫至關重要。

企業策略響應強調配方創新、通路夥伴關係和診斷整合，以應對臨床需求和供應鏈挑戰

主要企業洞察凸顯了產業參與者如何應對臨床需求、供應鏈複雜性和不斷變化的分銷模式。領先的開發商和供應商正在投資製劑創新，包括最佳化穩定性、減少對低溫運輸的依賴，以及擴展口服和鼻腔給藥方案以支持更大劑量給藥。其他公司也在改進其注射劑產品組合，以改善藥物動力學特徵和給藥便利性，同時繼續支持符合管理規範的指導方針和標籤最佳化。

製藥公司、飼料生產商和獸醫服務供應商之間的合作，能夠打造將治療產品與農場配送能力結合的一體化解決方案。擁有多元化分銷網路（包括與商業和農場飼料廠營運商、線上動物保健平台以及獨立和大型獸醫診所建立合作關係）的公司，能夠更好地管理特定管道的需求和監管差異。此外，面臨關稅和供應連續性挑戰的製造商正在探索區域和製造外包安排，以縮短供應鏈並提高應對力。

整合診斷支援和產品交付的公司能夠幫助臨床醫生提供標靶治療，並衡量介入措施的效果。商業性，將治療廣度、配送靈活性和診斷有效性相結合的公司能夠透過為生產商和獸醫提供臨床價值和營運效率，從而脫穎而出。

為製造商和經銷商提供實際有效的措施，以加強管理、供應鏈彈性以及治療和疫苗的農場可用性

針對產業領導者的可行建議重點在於使產品系列與管理目標保持一致，增強供應鏈韌性，並提升終端使用者的可及性。優先制定平衡治療方案與預防平台的組合策略，投資於降低發病率的疫苗技術以及支持符合管理要求的抗生素使用的製劑。同時，擴大給藥方式的開發，例如鼻腔給藥和口服飼料/飲水給藥，以減輕操作負擔，並促進在牛層面的干涉。

從營運角度來看，我們將在可行的情況下推行供應鏈多元化和近岸外包，以減輕關稅的影響，並確保關鍵原料和最終產品的持續供應。我們將加強與飼料廠、線上動物保健平台和獸醫網路的夥伴關係，創造能夠反映生產商實際獲取治療藥物和疫苗方式的一體化採購路徑。我們將投資於需要更嚴格溫度控制的減毒活病毒疫苗的低溫運輸最佳化，並考慮加強劑穩定性，以減少對複雜物流的依賴。

在商業性，我們將為獸醫和生產者開發教育和管理項目，強調以診斷主導的治療、合理的途徑選擇以及針對牛、牛和牛的年齡和生產特定通訊協定。我們將利用診斷工具和數據分析來展示干預效果，並設計定價和獲取模式，以支持小型和大型農場主，從而最大限度地提高採用率和臨床效果。

採用嚴格的多源研究途徑，結合領先的臨床醫師訪談、供應鏈映射和文獻綜合，提供可行的臨床和商業性見解

本報告所採用的調查方法結合了多源證據整合、專家諮詢和情境分析，以確保研究的穩健性和實務相關性。主要輸入包括與臨床醫生、牛衛生專業人員、飼料廠經理和分銷主管進行結構化訪談，以了解現場實踐和採購行為。這些定性見解與疫苗平台、抗生素類別和劑量科學的技術文獻進行了三角檢驗，以確保臨床嚴謹性並闡明其操作意義。

二級資訊來源包括同行評審期刊、監管指南文件以及公開的行業報告，這些報告闡明了治療機制、管理框架和物流考慮。調查方法也運用供應鏈圖譜來了解活性藥物成分、製劑成分和成品的採購路徑，從而識別潛在的瓶頸並制定應對關稅變化的適應策略。分析架構強調轉化相關性，著重於產品開發、分銷策略和臨床實施的可行洞察，而非定量的市場預測。

透過研究過程，我們將臨床醫生的觀點與獸醫實踐指南相匹配，並從分銷管道的相關人員那裡獲得反饋，檢驗了我們的研究結果能夠反映現實世界的限制和機會。

簡明摘要強調供應鏈適應性是整體預防、管理主導治療方法和永續疾病管理的基礎

總而言之，有效管理牛呼吸道疾病需要整合策略，將治療方法創新、給藥實用性和彈性分銷模式融為一體。疫苗技術和製劑科學的進步提供了有效的預防選擇，而先進的抗生素策略和管理實踐則能維持臨床病例的治療效果。給藥途徑的選擇必須考慮農場實踐、個別動物因素（例如成年牛、牛和牛）以及現有分銷管道的限制。

供應鏈動態，包括關稅調整的影響，凸顯了多元化和區域適應性的重要性。將產品設計與物流能力（例如注射劑、鼻腔給藥製劑以及口服飼料和飲水給藥）相結合的公司，將更有能力為來自不同地區的獸醫和生產商提供支援。最後，藥品開發商、飼料供應商、診斷供應商和獸醫網路之間的合作對於提供臨床合理、操作可行且與管理相符的解決方案至關重要，這些解決方案可以改善牛健康狀況並維持長期治療效果。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 整合長效抗生素降低BRD復發率
  • 制定精準抗生素管理通訊協定以抑制BRD抗藥性
  • 採用新型免疫調節劑增強牛對呼吸道病原體的天然防禦能力
  • 利用數位生物監測和人工智慧分析及早發現生物資源短缺 (BRD) 疫情
  • 針對牛呼吸道微生物群平衡的飼料添加劑輸送系統的研究進展
  • 基因編輯技術的出現增強了牛對呼吸道疾病的抵抗力

第6章 2025年美國關稅的累積影響

第7章 人工智慧的累積影響，2025年

第8章牛呼吸道疾病治療市場（依產品類型）

  • 抗生素
    • BETA-內醯胺類
    • Fluoroquinolones
    • 大環內酯類
      • 替米考星
      • 妥拉黴素
      • 泰樂菌素
    • 四環黴素
  • 疫苗
    • 惰性
      • BRSV
      • 巴氏桿菌
      • PI3
    • 活病毒疫苗
      • BRSV
      • 曼海姆亞屬
      • PI3

第九牛依給藥途徑分類的牛呼吸道疾病治療市場

  • 注射
    • 肌肉注射
    • 靜脈
    • 皮下
  • 鼻內
  • 口服
    • 餵食
    • 水

第10章牛呼吸道疾病治療市場（依動物類型）

  • 牛
    • 肉牛
    • 乳牛
  • 牛
    • 肉牛牛
    • 乳牛牛
  • 乳牛

第 11 章。牛呼吸道疾病治療市場（按通路）

  • 飼料廠
    • 商業工廠
    • 農場工廠
  • 網路藥局
    • 動物醫療平台
    • 一般零售
  • 獸醫診所
    • 獨立診所
    • 大型診所

第12章牛呼吸道疾病治療市場：按地區

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章牛隻呼吸道疾病治療市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

牛呼吸道疾病治療市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Zoetis Inc.
    • Boehringer Ingelheim International GmbH
    • Merck & Co., Inc.
    • Elanco Animal Health Incorporated
    • Ceva Sante Animale SA
    • Virbac SA
    • Phibro Animal Health Corporation
    • Vetoquinol SA
    • Dechra Pharmaceuticals PLC
    • Bimeda Inc.
Product Code: MRR-437D4595869F

The Bovine Respiratory Disease Treatment Market is projected to grow by USD 3.84 billion at a CAGR of 7.80% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.10 billion
Estimated Year [2025] USD 2.27 billion
Forecast Year [2032] USD 3.84 billion
CAGR (%) 7.80%

A strategic orientation to bovine respiratory disease treatment that aligns therapeutic choices with clinical realities, regulatory dynamics, and operational priorities

Bovine respiratory disease remains one of the most persistent and economically significant health challenges in cattle production systems globally. This introduction situates the reader at the intersection of clinical practice, pharmaceutical development, and supply chain evolution, highlighting how clinical drivers, regulatory pressures, and production economics collectively shape treatment strategies. The disease complex itself encompasses viral and bacterial etiologies that frequently require integrated therapeutic and preventive responses, and the interplay between antibiotics and vaccines is central to any effective control program.

Clinicians and herd managers increasingly rely on evidence-based protocols that balance animal welfare, antimicrobial stewardship, and operational efficiency. In this context, treatment selection is influenced by pathogen prevalence, animal category, route of administration suitability, and distribution channel accessibility. The landscape has been further complicated by shifting regulations and growing emphasis on reduced antimicrobial use, which amplifies the role of targeted vaccination programs and alternative delivery modalities.

This introduction therefore frames the subsequent analysis around four core dimensions: therapeutic modalities and formulations, administration routes and on-farm logistics, animal demographic considerations, and distribution ecosystems. By grounding the discussion in these pillars, readers will gain a practical orientation that supports strategic decisions in product development, clinical implementation, and commercial planning.

How scientific innovation, evolving administration methods, and distribution reconfiguration are reshaping treatment strategies and clinical practice paradigms

The treatment landscape for bovine respiratory disease is undergoing transformative shifts driven by scientific innovation, regulatory recalibration, and changing production practices. Advances in vaccine technology and formulation science are enabling broader preventive options, with inactivated and live attenuated platforms tailored to protect against core viral and bacterial agents. At the same time, refinement of antibiotic classes and dosing strategies is advancing antimicrobial stewardship objectives without sacrificing therapeutic potency for clinically ill animals.

Equally consequential are shifts in administration practices. Injectable delivery remains central to rapid systemic therapy, but intranasal vaccines and oral delivery via feed or water are gaining practical traction because they simplify mass administration and reduce handling stress. These changes intersect with animal demographics: protocols differ substantively between adult cattle populations, which include distinct beef and dairy management considerations, and younger cohorts such as beef calves and dairy calves where immune maturity and management systems affect both prevention and treatment timing.

Distribution systems are evolving in parallel. Traditional veterinary clinic channels continue to deliver clinical oversight and prescription-based treatments, yet feed mills-both commercial and onfarm-and online animal health platforms are reshaping access and procurement behaviors. Together, these trends are reconfiguring go-to-market strategies for product developers and suppliers, prompting new partnerships across pharmaceutical, feed, and veterinary service providers.

The practical ramifications of recent tariff policy updates on supply chains, procurement practices, and continuity of access for essential therapies in cattle health

Tariff policy developments in the United States for 2025 have influenced supply chain decisions, procurement tactics, and cost structures across the animal health ecosystem. Changes to import duties and customs protocols affect the flow of finished pharmaceuticals, vaccine components, and active ingredients, prompting manufacturers and distributors to reassess sourcing strategies and inventory positioning to preserve continuity of supply. Firms with complex global supply chains have been compelled to evaluate nearshoring, dual-sourcing, and strategic stockpiling as mitigants against tariff-driven disruptions.

These shifts have downstream effects on stakeholders from feed mill operators to veterinary clinics. Feed mills sourcing medicated premixes and onfarm mills procuring therapeutics now face altered landed costs that can impact the pricing and availability of oral medications administered via feed or water. Similarly, online animal health platforms and general eRetailers importing niche formulations may adjust catalog offerings to manage margin pressures or compliance complexity. For animal producers, the practical implication is increased attention to procurement timelines and supplier reliability, as well as a renewed focus on preventive measures such as vaccination campaigns that reduce reliance on imported therapeutic products.

Regulatory harmonization and trade facilitation efforts remain important variables. Where tariff changes create friction, collaborative industry responses-such as pooled procurement, supplier diversification, and local formulation development-are emerging as pragmatic adaptations. These responses prioritize uninterrupted access to essential therapies and vaccines while maintaining adherence to clinical protocols and stewardship commitments.

An in-depth segmentation perspective linking therapeutic categories, administration routes, animal demographics, and distribution pathways to clinical and commercial strategies

Segmentation insights reveal differentiated opportunities and clinical considerations across product classes, administration routes, animal types, and distribution pathways. Within product type, antibiotics encompass distinct pharmacological families including beta lactams, fluoroquinolones, macrolides, and tetracyclines, with macrolides further represented by agents such as tilmicosin, tulathromycin, and tylosin. Vaccines occupy preventive space and are stratified into inactivated platforms targeting pathogens like bovine respiratory syncytial virus, Pasteurella and parainfluenza 3, and live attenuated formulations that also target BRSV, Mannheimia, and PI3, each with different immunogenic profiles and cold-chain implications.

Route of administration is a pivotal segmentation lens: injectable therapies are administered intramuscularly, intravenously or subcutaneously and remain the standard when systemic concentrations and rapid onset are required. Intranasal delivery offers localized immune priming especially valuable in young stock, while oral routes administered through feed or water enable mass medication strategies that reduce handling but require careful dosing control and palatability considerations. Animal type further differentiates clinical protocols; adult cattle populations, encompassing both beef and dairy cattle, have distinct production objectives and stewardship constraints compared with calves and heifers where immune competence and management system vulnerability influence timing and regimen selection. Calves in beef and dairy systems may necessitate earlier preventive interventions and tailored therapeutic approaches.

Distribution channel segmentation highlights the service and logistics dimension. Feed mills-both commercial and onfarm-play a role in delivering medicated feeds and supporting oral administration strategies. Online pharmacies operate as animal health platforms and generalized eRetail channels, broadening access to products where regulatory frameworks permit. Veterinary clinics, from independent practices to large multi-site groups, continue to provide clinical oversight, diagnostics, and prescription-based therapies. Understanding these intersecting segments enables stakeholders to align product development, packaging, cold-chain design, and commercial models with end-user requirements and operational realities.

How regional production systems, regulatory environments, and distribution infrastructures are shaping differentiated treatment approaches and deployment strategies

Regional dynamics shape clinical priorities, regulatory expectations, and distribution strategies across the Americas, Europe, Middle East & Africa, and the Asia-Pacific. In the Americas, production systems span large-scale commercial feedlots to family-run dairy operations, yielding diverse treatment needs and a strong emphasis on stewardship programs and traceability. Vaccination campaigns and targeted antibiotic regimens are coordinated through veterinary networks and integrated supply chains, with feed mills and veterinary clinics playing prominent roles in product distribution.

Within Europe, Middle East & Africa, regulatory frameworks and stewardship initiatives often drive conservative antibiotic use and increased adoption of preventive strategies. This region demonstrates variable infrastructure capacity, from highly developed cold-chain systems in parts of Europe to more fragmented distribution networks in some Middle Eastern and African markets, which influences the practical adoption of live attenuated vaccines and injectable formulations. The Asia-Pacific region is characterized by rapid growth in intensive production systems, diverse regulatory environments, and an expanding role for online animal health platforms and commercial feed mills. In many Asia-Pacific markets, the scale of production and proximity to manufacturing hubs create unique logistics advantages and challenges, particularly around feed- and water-administered therapies.

Across regions, the practical implications for stakeholders include alignment of product formats with logistical realities, sensitivity to regulatory and stewardship frameworks, and tailoring of commercial approaches to local procurement behaviors. Cross-regional knowledge transfer and adaptive implementation strategies are therefore essential for successful deployment of therapeutics and preventive programs.

Strategic corporate responses highlighting formulation innovation, channel partnerships, and diagnostic integration to meet clinical needs and supply chain challenges

Key company insights emphasize how industry participants are responding to clinical demands, supply chain complexity, and shifting distribution models. Leading developers and suppliers are investing in formulation innovation to optimize stability, reduce cold-chain dependency, and expand oral and intranasal options that facilitate mass administration. Others are refining injectable portfolios to improve pharmacokinetic profiles and dosing convenience, while continuing to support stewardship-aligned guidance and label optimization.

Strategic partnerships are increasingly important; collaborations between pharmaceutical firms, feed producers, and veterinary service providers enable integrated solutions that align therapeutic products with onfarm delivery capabilities. Companies with diversified distribution networks, including relationships with commercial and onfarm feed mill operators, online animal health platforms, and both independent and large veterinary practices, are better positioned to manage channel-specific demands and regulatory nuances. Additionally, manufacturers addressing tariff and supply continuity challenges are exploring regional manufacturing and contract manufacturing arrangements to shorten supply lines and enhance responsiveness.

innovation in diagnostics and data-driven health management is another focal area, as companies that integrate diagnostic support with product offerings help clinicians implement targeted therapies and measure intervention outcomes. The commercial implication is that companies combining therapeutic breadth, distribution agility, and diagnostic enablement can differentiate by delivering both clinical value and operational efficiencies to producers and veterinarians.

Practical, high-impact steps for manufacturers and distributors to strengthen stewardship, supply chain resilience, and on-farm accessibility of treatments and vaccines

Actionable recommendations for industry leaders focus on aligning product portfolios with stewardship goals, strengthening supply chain resilience, and enhancing end-user accessibility. Prioritize portfolio strategies that balance therapeutic options and preventive platforms, investing in vaccine technologies that reduce disease incidence and in formulations that support stewardship-compliant antibiotic use. Simultaneously, expand development into administration modalities such as intranasal and oral feed or water delivery to lower handling burdens and facilitate herd-level interventions.

Operationally, pursue supply chain diversification and nearshoring where feasible to mitigate tariff exposure and ensure uninterrupted access to critical raw materials and finished products. Strengthen partnerships with feed mills, online animal health platforms, and veterinary networks to create integrated procurement pathways that reflect how producers obtain therapeutics and vaccines in practice. Invest in cold-chain optimization where live attenuated vaccines demand stricter temperature control, while exploring formulation stability enhancements that reduce dependency on complex logistics.

Commercially, develop education and stewardship programs aimed at veterinarians and producers that emphasize diagnostic-led treatment, appropriate route selection, and age- and production-specific protocols for adult cattle, calves, and heifers. Leverage diagnostic tools and data analytics to demonstrate intervention outcomes, and design pricing and access models that support both smallholder and large-scale operations to maximize adoption and clinical impact.

A rigorous, multi-source research approach combining frontline clinician interviews, supply chain mapping, and literature synthesis to produce actionable clinical and commercial insights

The research methodology underpinning this report integrates multi-source evidence synthesis, expert consultation, and scenario-based analysis to ensure robustness and practical relevance. Primary inputs included structured interviews with clinicians, herd health specialists, feed mill managers, and distribution executives to capture frontline practices and procurement behaviors. These qualitative insights were triangulated with technical literature on vaccine platforms, antibiotic classes, and administration science to ensure clinical accuracy and to contextualize operational implications.

Secondary sources comprised peer-reviewed journals, regulatory guidance documents, and publicly available industry reports that elucidate therapeutic mechanisms, stewardship frameworks, and logistics considerations. The methodology also applied supply chain mapping to understand sourcing pathways for active pharmaceutical ingredients, formulation components, and finished goods, allowing identification of potential chokepoints and adaptive strategies in response to tariff changes. Analytical frameworks emphasized translational relevance, focusing on actionable insights for product development, distribution strategy, and clinical implementation rather than quantitative market projections.

Throughout the research process, findings were validated by cross-checking clinician perspectives against veterinary practice guidelines and by obtaining feedback from distribution channel stakeholders to ensure that recommendations reflect real-world constraints and opportunities.

A concise synthesis emphasizing integrated prevention, stewardship-led therapeutics, and supply chain adaptability as the foundation for durable disease control

In conclusion, effective management of bovine respiratory disease requires integrated strategies that bridge therapeutic innovation, administration practicality, and resilient distribution models. Advancements in vaccine technology and formulation science provide meaningful preventive options, while refined antibiotic strategies and stewardship practices preserve therapeutic effectiveness for clinical cases. The choice of administration route must reflect operational realities on farm, individual animal factors such as adult cattle, calves, and heifers, and the constraints of available distribution channels.

Supply chain dynamics, including the implications of tariff adjustments, underscore the importance of diversification and regional adaptability. Companies that align product design with logistical capabilities-such as injectable formats, intranasal options, and oral feed- and water-administered therapies-will be better positioned to support veterinarians and producers across varied regional contexts. Finally, collaboration across pharmaceutical developers, feed suppliers, diagnostic providers, and veterinary networks is essential to deliver clinically sound, operationally feasible, and stewardship-aligned solutions that improve herd health outcomes and sustain long-term therapeutic efficacy.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of long-acting antibiotic formulations to reduce BRD relapse rates
  • 5.2. Development of precision antimicrobial stewardship protocols to curb BRD resistance
  • 5.3. Adoption of novel immunomodulators enhancing bovine innate defenses against respiratory pathogens
  • 5.4. Utilization of digital biosurveillance and AI analytics for early detection of BRD outbreaks
  • 5.5. Advances in feed additive delivery systems targeting respiratory microbiome balance in cattle
  • 5.6. Emergence of gene-editing techniques to enhance bovine resistance to respiratory disease challenges

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bovine Respiratory Disease Treatment Market, by Product Type

  • 8.1. Antibiotics
    • 8.1.1. Beta Lactams
    • 8.1.2. Fluoroquinolones
    • 8.1.3. Macrolides
      • 8.1.3.1. Tilmicosin
      • 8.1.3.2. Tulathromycin
      • 8.1.3.3. Tylosin
    • 8.1.4. Tetracyclines
  • 8.2. Vaccines
    • 8.2.1. Inactivated
      • 8.2.1.1. BRSV
      • 8.2.1.2. Pasteurella
      • 8.2.1.3. PI3
    • 8.2.2. Live Attenuated
      • 8.2.2.1. BRSV
      • 8.2.2.2. Mannheimia
      • 8.2.2.3. PI3

9. Bovine Respiratory Disease Treatment Market, by Route Of Administration

  • 9.1. Injectable
    • 9.1.1. Intramuscular
    • 9.1.2. Intravenous
    • 9.1.3. Subcutaneous
  • 9.2. Intranasal
  • 9.3. Oral
    • 9.3.1. Feed
    • 9.3.2. Water

10. Bovine Respiratory Disease Treatment Market, by Animal Type

  • 10.1. Adult Cattle
    • 10.1.1. Beef Cattle
    • 10.1.2. Dairy Cows
  • 10.2. Calves
    • 10.2.1. Beef Calves
    • 10.2.2. Dairy Calves
  • 10.3. Heifers

11. Bovine Respiratory Disease Treatment Market, by Distribution Channel

  • 11.1. Feed Mills
    • 11.1.1. Commercial Mills
    • 11.1.2. Onfarm Mills
  • 11.2. Online Pharmacies
    • 11.2.1. Animal Health Platforms
    • 11.2.2. General ERetail
  • 11.3. Veterinary Clinics
    • 11.3.1. Independent Clinics
    • 11.3.2. Large Practices

12. Bovine Respiratory Disease Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Bovine Respiratory Disease Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Bovine Respiratory Disease Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Zoetis Inc.
    • 15.3.2. Boehringer Ingelheim International GmbH
    • 15.3.3. Merck & Co., Inc.
    • 15.3.4. Elanco Animal Health Incorporated
    • 15.3.5. Ceva Sante Animale S.A.
    • 15.3.6. Virbac S.A.
    • 15.3.7. Phibro Animal Health Corporation
    • 15.3.8. Vetoquinol S.A.
    • 15.3.9. Dechra Pharmaceuticals PLC
    • 15.3.10. Bimeda Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BOVINE RESPIRATORY DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. BOVINE RESPIRATORY DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BOVINE RESPIRATORY DISEASE TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BETA LACTAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BETA LACTAMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BETA LACTAMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BETA LACTAMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BETA LACTAMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BETA LACTAMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FLUOROQUINOLONES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FLUOROQUINOLONES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FLUOROQUINOLONES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FLUOROQUINOLONES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MACROLIDES, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MACROLIDES, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MACROLIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MACROLIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TILMICOSIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TILMICOSIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TILMICOSIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TILMICOSIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TILMICOSIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TILMICOSIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TULATHROMYCIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TULATHROMYCIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TULATHROMYCIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TULATHROMYCIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TULATHROMYCIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TULATHROMYCIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TYLOSIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TYLOSIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TYLOSIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TYLOSIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TYLOSIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TYLOSIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TETRACYCLINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INACTIVATED, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INACTIVATED, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INACTIVATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INACTIVATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BRSV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BRSV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BRSV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BRSV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BRSV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BRSV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PASTEURELLA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PASTEURELLA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PASTEURELLA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PASTEURELLA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PASTEURELLA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PASTEURELLA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PI3, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PI3, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PI3, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PI3, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PI3, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PI3, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LIVE ATTENUATED, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LIVE ATTENUATED, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BRSV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BRSV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BRSV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BRSV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BRSV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BRSV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MANNHEIMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MANNHEIMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MANNHEIMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MANNHEIMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MANNHEIMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY MANNHEIMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PI3, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PI3, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PI3, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PI3, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PI3, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY PI3, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRANASAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRANASAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRANASAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRANASAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INTRANASAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY WATER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY WATER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY WATER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY WATER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY WATER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY WATER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ADULT CATTLE, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ADULT CATTLE, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ADULT CATTLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ADULT CATTLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ADULT CATTLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ADULT CATTLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ADULT CATTLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ADULT CATTLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BEEF CATTLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BEEF CATTLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BEEF CATTLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BEEF CATTLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BEEF CATTLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BEEF CATTLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DAIRY COWS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DAIRY COWS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DAIRY COWS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DAIRY COWS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DAIRY COWS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DAIRY COWS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY CALVES, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY CALVES, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY CALVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY CALVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY CALVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY CALVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY CALVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY CALVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BEEF CALVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BEEF CALVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BEEF CALVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BEEF CALVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BEEF CALVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY BEEF CALVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DAIRY CALVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DAIRY CALVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DAIRY CALVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DAIRY CALVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DAIRY CALVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DAIRY CALVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY HEIFERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY HEIFERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY HEIFERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY HEIFERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY HEIFERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY HEIFERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED MILLS, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED MILLS, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED MILLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED MILLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED MILLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED MILLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED MILLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY FEED MILLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COMMERCIAL MILLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COMMERCIAL MILLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COMMERCIAL MILLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COMMERCIAL MILLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COMMERCIAL MILLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY COMMERCIAL MILLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONFARM MILLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONFARM MILLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONFARM MILLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONFARM MILLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONFARM MILLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONFARM MILLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANIMAL HEALTH PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANIMAL HEALTH PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANIMAL HEALTH PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANIMAL HEALTH PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANIMAL HEALTH PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY ANIMAL HEALTH PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY GENERAL ERETAIL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY GENERAL ERETAIL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY GENERAL ERETAIL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY GENERAL ERETAIL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY GENERAL ERETAIL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY GENERAL ERETAIL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VETERINARY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VETERINARY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INDEPENDENT CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INDEPENDENT CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INDEPENDENT CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INDEPENDENT CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INDEPENDENT CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY INDEPENDENT CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LARGE PRACTICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LARGE PRACTICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LARGE PRACTICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, BY LARGE PRACTICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL BOVINE RESPIRATORY DISEASE TREATMENT MARKET SIZE, B